Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer-specific and overall mortality: A modeling approach.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
12
07
2022
received:
14
03
2022
accepted:
18
07
2022
pubmed:
26
8
2022
medline:
28
9
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
To validate cancer screening programs, experts recommend estimating effects on case fatality rates (CFRs) and cancer-specific mortality. This study evaluates hepatocellular carcinoma (HCC) screening in patients with cirrhosis for those outcomes using a modeling approach. We designed a Markov model to assess 10-year HCC-CFR, HCC-related, and overall mortality per 100,000 screened patients with compensated cirrhosis. The model evaluates different HCC surveillance intervals (none, annual [12 months], semiannual [6 months], or quarterly [3 months]) and imaging modalities (ultrasound [US] or magnetic resonance imaging [MRI]) in various annual incidences (0.2%, 0.4%, or 1.5%). Compared to no surveillance, 6-month US reduced the 10-year HCC-CFR from 77% to 46%. With annual incidences of 0.2%, 0.4%, and 1.5%, the model predicted 281, 565, and 2059 fewer HCC-related deaths, respectively, and 187, 374, and 1356 fewer total deaths per 100,000 screened patients, respectively. Combining alpha-fetoprotein screening to 6-month US led to 32, 63, and 230 fewer HCC-related deaths per 100,000 screened patients for annual incidences of 0.2%, 0.4%, and 1.5%, respectively. Compared to 6-month US, 3-month US reduced cancer-related mortality by 14%, predicting 61, 123, and 446 fewer HCC-related deaths per 100,000 screened patients with annual incidences of 0.2%, 0.4%, and 1.5%, respectively. Compared to 6-month US, 6-month MRI (-17%) and 12-month MRI (-6%) reduced HCC-related mortality. Compared to 6-month US, overall mortality reductions ranged from -0.1% to -1.3% when using 3-month US or MRI. A US surveillance interval of 6 months improves HCC-related and overall mortality compared to no surveillance. A shorter US interval or using MRI could reduce HCC-CFR and HCC-related mortality, with a modest effect on overall mortality.
Identifiants
pubmed: 36004703
doi: 10.1002/hep4.2059
pmc: PMC9512473
doi:
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2964-2974Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
J Hepatol. 2015 Nov;63(5):1156-63
pubmed: 26100498
Ann Oncol. 2016 Sep;27(suppl 5):v103-v110
pubmed: 27664246
Gut. 2001 Feb;48(2):251-9
pubmed: 11156649
BMJ. 2011 Oct 13;343:d6395
pubmed: 21998347
Gastroenterology. 2018 Aug;155(2):443-457.e17
pubmed: 29733831
Hepatology. 2020 Nov;72(5):1654-1665
pubmed: 32017165
Hepatology. 2015 Sep;62(3):737-50
pubmed: 25678021
Hepatology. 2018 Jul;68(1):78-88
pubmed: 29023828
Gastroenterology. 2014 Oct;147(4):935-6
pubmed: 25150788
Gut. 2017 Feb;66(2):330-341
pubmed: 26511797
Gastroenterology. 2018 Aug;155(2):431-442.e10
pubmed: 29729258
PLoS Med. 2014 Apr 01;11(4):e1001624
pubmed: 24691105
J Clin Oncol. 2015 Jan 10;33(2):209-17
pubmed: 25452455
Am J Gastroenterol. 2015 Aug;110(8):1149-58
pubmed: 26169512
Cancer Med. 2019 Oct;8(13):6127-6138
pubmed: 31422585
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Cancer. 1989 Jun 1;63(11):2207-10
pubmed: 2541886
Scand J Gastroenterol. 2010 Mar;45(3):332-9
pubmed: 20001605
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Gastroenterology. 1985 Aug;89(2):259-66
pubmed: 2408960
J Hepatol. 2017 Oct 06;:
pubmed: 28989094
BMJ. 2016 Jan 06;352:h6080
pubmed: 26740343
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hepatology. 2016 Oct;64(4):1136-47
pubmed: 27348075
Am J Med. 1996 Oct;101(4):422-34
pubmed: 8873514
JAMA. 2019 Sep 3;322(9):843-856
pubmed: 31479136
Dig Dis Sci. 2017 Oct;62(10):2923-2931
pubmed: 28815349
J Hepatol. 2018 Dec;69(6):1274-1283
pubmed: 30092234
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Gastroenterology. 2021 Sep;161(3):1060-1062.e3
pubmed: 34058214
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Am J Gastroenterol. 2017 Nov;112(11):1634-1635
pubmed: 29016563
Cancer. 1961 Nov-Dec;14:1272-94
pubmed: 13909709
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
N Engl J Med. 2016 Oct 13;375(15):1438-1447
pubmed: 27732805
J Surg Oncol. 2021 Feb;123(2):381-388
pubmed: 33174627
Gastroenterology. 2018 May;154(6):1706-1718.e1
pubmed: 29425931
Hepatology. 2011 Dec;54(6):1987-97
pubmed: 22144108
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
J Hepatol. 2014 Aug;61(2):333-41
pubmed: 24717522
N Engl J Med. 2013 Sep 19;369(12):1106-14
pubmed: 24047060
J Hepatol. 2010 Aug;53(2):291-7
pubmed: 20483497
Hepatol Commun. 2022 Oct;6(10):2964-2974
pubmed: 36004703
Hepatology. 2014 Apr;59(4):1471-81
pubmed: 24677195
Am J Gastroenterol. 2020 Oct;115(10):1642-1649
pubmed: 32530829